Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1
{{output}}
Introduction: Treatment options are limited for patients with advanced NSCLC who progress on anti-programmed cell death-ligand 1 (anti-PD-L1) monotherapy. Second-line platinum-based chemotherapy provides a short progression-free ... ...
